Charles River Laboratories Intl. Inc vs MINISO Group Holding Ltd — how do they compare? Charles River Laboratories Intl. Inc trades at $302.47 (market cap $14.23B), while MINISO Group Holding Ltd trades at $9.58 (market cap $2.65B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 5.4× MINISO Group Holding Ltd's market cap, and MINISO Group Holding Ltd pays a 7.34% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and MINISO Group Holding Ltd for 24 Days on average.
| CRL | MNSO | |
|---|---|---|
Market Cap | $14.23B | $2.65B |
Volume | 1,176,885 | 747,763 |
Sector | Health | Consumer Cyclical |
52-Week High | $310.77 | $22.75 |
52-Week Low | $149.93 | $8.60 |
Typical Hold Time | 33 Days | 24 Days |
Enterprise Value | $17.06B | $3.52B |
Dividend Yield | — | 7.34% |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.53, up 0.08% on the day, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, though it faces profitability challenges with a negative net income margin and ROE. Recent investor day presentations highlighted a strategic plan targeting 5-7% revenue growth and $300 million in savings by 2030, driving positive sentiment.
The outlook is cautiously optimistic, supported by analyst buy ratings and a $305.50 consensus price target, but risks include ongoing margin pressure, volatile non-human primate costs, and a high valuation multiple. Earnings growth and successful execution of the new strategic plan are critical for sustained upside.
MNSO trades at $8.94, up 0.34% on the day, with a bearish technical signal from moving averages and a mixed earnings history. The company reported 2025 revenue of $21.44 billion and net income of $1.21 billion, with a P/E of 14.76 and P/S of 0.79 indicating reasonable valuation. Recent news highlights CFO share purchases and earnings volatility, with analyst consensus leaning bullish at 60% buy ratings.
The outlook for MNSO balances growth potential from domestic expansion against earnings inconsistency and competitive pressures. Investment appeal lies in its value metrics and operational scale, but risks include margin compression and market sentiment shifts. The stock's near-term direction hinges on sustained profitability improvements and macroeconomic conditions.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →